Acumen Pharmaceuticals, Inc.
ABOS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $12 |
| Gross Profit | $0 | $0 | $0 | -$12 |
| % Margin | – | – | – | – |
| R&D Expenses | $94 | $42 | $32 | $12 |
| G&A Expenses | $20 | $19 | $13 | $7 |
| SG&A Expenses | $20 | $19 | $13 | $7 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$12 |
| Operating Expenses | $114 | $61 | $45 | $7 |
| Operating Income | -$114 | -$61 | -$45 | -$20 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $12 | $9 | $2 | -$81 |
| Pre-Tax Income | -$102 | -$52 | -$43 | -$101 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$102 | -$52 | -$43 | -$101 |
| % Margin | – | – | – | – |
| EPS | -1.71 | -1.08 | -1.06 | -2.63 |
| % Growth | -58.3% | -1.9% | 59.7% | – |
| EPS Diluted | -1.71 | -1.08 | -1.06 | -2.63 |
| Weighted Avg Shares Out | 60 | 48 | 41 | 38 |
| Weighted Avg Shares Out Dil | 60 | 49 | 41 | 38 |
| Supplemental Information | – | – | – | – |
| Interest Income | $14 | $11 | $2 | $0 |
| Interest Expense | $4 | $1 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$98 | -$52 | -$43 | -$20 |
| % Margin | – | – | – | – |